TCON — TRACON Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- $0.15m
- -$6.12m
- $12.05m
- 41
- 93
- 14
- 47
Annual income statement for TRACON Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0.346 | 0 | 12 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 22.3 | 16.2 | 28.7 | 27.9 | 21.3 |
| Operating Profit | -22.3 | -16.2 | -28.3 | -27.9 | -9.27 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -22.7 | -16.8 | -28.7 | -29.1 | -3.59 |
| Net Income After Taxes | -22.7 | -16.8 | -28.7 | -29.1 | -3.59 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -22.7 | -16.8 | -28.7 | -29.1 | -3.59 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -22.7 | -16.8 | -28.7 | -29.1 | -3.59 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -149 | -37.3 | -33.2 | -27.9 | -0.741 |